TICKERNERD
Menu
TGTXTGTXHealthcare · Biotechnology

TGTX Stock Forecast: TG Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$56
+3.21% on the day

The 8 Wall Street analysts covering TG Therapeutics, Inc. hold a median 12-month price target of $75 — +33.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$8.3B
Ticker Nerd rank
67 / 100
Median analyst target
$75
Analysts covering
8
Revenue$240.3M+70.3% y/y
Operating income$21.7M
Net income$7.8M
Free cash flow$39.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+13.7%
1M
−0.1%
YTD
+87.9%
1Y
+90.2%
From 52W high
−5.2%
From 52W low
+107.9%
$27
$59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TGTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TG Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
92
Volatility
83
Growth
82
Momentum
76
Revisions
50
Issuance
34
Size
18
Accruals
10

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TGTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TGTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Oct 25Jan 26Apr 26Jul 26TGTXHigh $86Median $75Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy0 Hold1 Sell
Low $21Median $75High $86

The green dot is the last close — the median target sits +33.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026JP MorganMaintainsOverweight$65 → $72
27 July 2026B. Riley SecuritiesMaintainsBuy$55 → $86
27 July 2026B. Riley SecuritiesMaintainsBuy—
13 July 2026HC Wainwright & Co.MaintainsBuy$70 → $77
13 July 2026HC Wainwright & Co.MaintainsBuy—
7 July 2026B of A SecuritiesMaintainsUnderperform$17 → $20
7 July 2026B of A SecuritiesMaintainsUnderperform—
6 July 2026HC Wainwright & Co.ReiteratesBuy$70
6 July 2026HC Wainwright & Co.ReiteratesBuy—
27 May 2026HC Wainwright & Co.ReiteratesBuy—
6 May 2026HC Wainwright & Co.MaintainsBuy—
2 Feb 2026JP MorganMaintainsOverweight—
15 Jan 2026Goldman SachsMaintainsNeutral—
3 Nov 2025JP MorganMaintainsOverweight—
6 Oct 2025HC Wainwright & Co.AssumesBuy$60
17 Sept 2025B. Riley SecuritiesMaintainsBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Jan 2025HC Wainwright & Co.ReiteratesBuy—
25 Nov 2024JP MorganMaintainsOverweight—
5 Nov 2024Goldman SachsMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TGTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TGTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, TG Therapeutics, Inc. returned +90.2% against +19.6% for the S&P 500, dividends included.

TGTX vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Oct 25Jan 26Apr 26Jul 26TGTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TGTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−38.1%
Analysts raising
0
Analysts cutting
3
Fundamentals

TG Therapeutics, Inc. (TGTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.8×

Cheaper than 39% of US stocks

Price / sales
10.4×

Cheaper than 14% of US stocks

Price / book
13.2×

Cheaper than 8% of US stocks

EV / EBITDA
57.9×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
70.3%

Higher than 90% of US stocks

Earnings growth (YoY)
−72.4%

Higher than 6% of US stocks

Gross margin
82.9%

Higher than 93% of US stocks

Operating margin
9.0%

Higher than 62% of US stocks

Net margin
55.2%

Higher than 97% of US stocks

Returns & dividend
Return on equity
100.3%

Higher than 96% of US stocks

Return on assets
7.3%

Higher than 86% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TG Therapeutics, Inc. (TGTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TG Therapeutics, Inc. has a market value of $8.3B and an enterprise value of $7.9B.

  • Revenue in the twelve months to 30 June 2026: $799.5M. The latest quarter grew 70.3% year on year.

  • Net income over the same four quarters: $441.5M, a 55.2% net margin.

  • Diluted earnings per share, trailing twelve months: $2.74.

  • Free cash flow in the twelve months to 30 June 2026: $17.4M.

  • TG Therapeutics, Inc. spent $178.2M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 153.1M.

  • Trailing P/E: 19.8×; forward P/E: 18.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • TG Therapeutics, Inc. employs 399 people — $2.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

TGTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TGTXTG Therapeutics, Inc.$8.3B
67
CRNXCrinetics Pharmaceuticals, Inc.$8.7B
74
PCVXVaxcyte, Inc.$8.9B
51
IMVTImmunovant, Inc.$8.9B
41
IBRXImmunityBio, Inc.$8.2B
48
SYRESpyre Therapeutics, Inc.$9.2B
47
IONSIonis Pharmaceuticals, Inc.$9.5B
47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TG Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TGTX news & analysis

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

Seeking Alpha · 22 Aug 2026positive

Shares of TG Therapeutics rose this week after buyout rumors surfaced, with the company seen as a takeover target given Briumvi's growth and the de-risking of its recent subcutaneous formulation. The piece highlights strong standalone prospects regardless of merger-and-acquisition outcomes.

Why it matters — A TGTX watcher would care because buyout speculation, alongside Briumvi's growth and development milestones, could influence how the stock is valued in the near term.

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection

MarketBeat · 18 Aug 2026neutral

At a TG Therapeutics conference, 908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following its divestiture of its life-sciences business line about 15 months ago.

Why it matters — TGTX watchers may follow conference coverage from peers, though this item concerns 908 Devices' strategic pivot rather than TG Therapeutics itself.

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

Seeking Alpha · 3 Aug 2026positive

Following a Q2 selloff, the author maintains a Buy rating on TG Therapeutics, citing BRIUMVI's 64% YoY revenue surge to $228 million and guidance of $950 million by 2026, though net income was pressured by manufacturing investments.

Why it matters — A TGTX watcher would care because BRIUMVI's strong revenue growth and upcoming Phase 3 data for subcutaneous administration could meaningfully expand the company's multiple sclerosis franchise and improve future margins.

TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down

Zacks Investment Research · 3 Aug 2026neutral

TG Therapeutics missed Q2 earnings estimates, while revenue rose year over year on strong Briumvi demand. The company raised its 2026 revenue guidance, and the stock fell following the report.

Why it matters — The report mixes an earnings miss with rising Briumvi-driven revenue and higher 2026 guidance, offering conflicting signals on the company's near-term performance and outlook.

TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 3 Aug 2026neutral

TG Therapeutics held its Q2 2026 earnings call, during which management discussed the company's financial results and business updates for the quarter.

Why it matters — The earnings call provides direct insight from management on TG Therapeutics' recent performance and strategic direction, which is closely watched by investors.

FAQ

Frequently asked questions about TGTX stock

What is the TGTX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering TG Therapeutics, Inc. have a median 12-month price target of $75, with estimates ranging from $21 to $86. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TGTX stock a buy right now?

Of the 8 analysts covering TG Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks TG Therapeutics, Inc. 67 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TGTX?

As at 22 Aug 2026, TG Therapeutics, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will TGTX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +33.9% from the last close, and Ticker Nerd's factor model ranks TG Therapeutics, Inc. 67 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TGTX stock forecast for 2030?

No analyst covering TG Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $86 over the next 12 months.

How has TGTX stock performed over the past year?

TG Therapeutics, Inc. returned +90.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TG Therapeutics, Inc. do?

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing novel therapies for B‑cell mediated diseases.

What is the latest news on TGTX?

The most recent item we track (Seeking Alpha, 22 Aug 2026): "TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors". Shares of TG Therapeutics rose this week after buyout rumors surfaced, with the company seen as a takeover target given Briumvi's growth and the de-risking of its recent subcutaneous formulation. The piece highlights strong standalone prospects regardless of merger-and-acquisition outcomes.

Company

About TG Therapeutics, Inc.

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing novel therapies for B‑cell mediated diseases. The company’s primary commercial product is BRIUMVI, an anti‑CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis, addressing clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease. TG Therapeutics also maintains a pipeline targeting B‑cell malignancies and autoimmune disorders, including candidates such as TG‑1701, an oral covalent Bruton’s tyrosine kinase (BTK) inhibitor, Azer‑Cel, an allogeneic CD19 CAR T therapy, and TG‑1801, an anti‑CD47/CD19 bispecific antibody, primarily in early-stage clinical development. The company generates most of its revenue from BRIUMVI sales in the United States, with additional contributions from international markets. TG Therapeutics, Inc., founded in 1993 and headquartered in Morrisville, North Carolina, operates within the health sector as a specialized player in immunology and oncology, aiming to provide targeted treatments for complex B‑cell driven conditions.

CEO Mr. Michael S. Weiss Esq., J.D. · 399 employees · United States · https://www.tgtherapeutics.com